(4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone-D7 (Fenofibrate Impurity)
实时
已添加到 RFQ
仅供研究与分析用途。不可个人使用。
包装与处理
所示为供视觉参考的示意性产品包装。实际包装可能因包装规格、数量、储存条件和运输要求而异。
可提供文档
可应要求提供详细规格、证书和支持性文件。
可应要求提供详细规格、证书和支持性文件。
储存: 完整信息请参阅 MSDS。
危害: 完整信息请参阅 MSDS。
(4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone-D7 (Fenofibrate Impurity) 产品信息
(4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone-D7 (Fenofibrate Impurity) 归类于 Impurity,用于分析研究、质量控制和药物对照品应用。 其关联物质为 Fenofibrate. 本产品由 Clearsynth 提供,目录号为 CS-T-96827.
Clearsynth 提供该化合物用于研究和分析用途,产品信息包括 CAS 号、分子式、分子量和产品咨询详情。
技术数据
产品名称
(4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone-D7 (Fenofibrate Impurity)
CAT 编号
CS-T-96827
HSN 代码
38229010
原产国
Can be shipped from India, Canada and USA
分子式
C16H8D7ClO2
分子量
281.79
类别
API 系列
储存条件
完整信息请参阅 MSDS。
危险化合物
完整信息请参阅 MSDS。
描述
法规说明
(4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone-D7 (Fenofibrate Impurity) is supplied with detailed characterization data compliant with regulatory guideline. (4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone-D7 (Fenofibrate Impurity) can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Fenofibrate.
概述
"(4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone-D7 is a labelled analogue of (4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone (C375150), an impurity of Fenofibrate (F248640). Fenofibrate is a lipid regulating drug that is used to decrease the incidence of coronary disease. It is also used in patients who frequently experience dyslipidemia and hyperlipoproteinemia as a result of renal insufficiencies."
同义词
(4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone-D7 (Fenofibrate Impurity)
应用说明
"(4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone-D7 is a labelled analogue of (4-Chlorophenyl)[4-(1-methylethoxy)phenyl]methanone (C375150), an impurity of Fenofibrate (F248640). Fenofibrate is a lipid regulating drug that is used to decrease the incidence of coronary disease. It is also used in patients who frequently experience dyslipidemia and hyperlipoproteinemia as a result of renal insufficiencies."
产品应用与法规搜索词
此参考标准的有用产品、供应商和法规搜索词。